Nathan Cantoni
Overview
Explore the profile of Nathan Cantoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rovo A, Cantoni N, Samii K, Rufer A, Koenen G, Ivic S, et al.
PLoS One
. 2022 Apr;
17(4):e0267342.
PMID: 35446925
Aims Of The Study: Thrombopoietin receptor agonists (TPO-RAs) are approved for immune thrombocytopenia (ITP), but their impact on health-related quality of life (HRQoL) remains poorly investigated in clinical practice. This...
12.
Adam F, Szybinski J, Halter J, Cantoni N, Wenzel F, Leonards K, et al.
Curr Oncol
. 2022 Feb;
29(2):805-815.
PMID: 35200567
Chronic neutrophilic leukemia (CNL) relates to mutational CSF3R activation with membrane proximal mutations such as T618I as driver mutations, but the significance of truncating mutations is not clarified. In CNL,...
13.
Bana M, Ribi K, Peters S, Kropf-Staub S, Naf E, Zurcher-Florin S, et al.
Cancer Nurs
. 2021 Sep;
44(6):E687-E702.
PMID: 34507338
Background: The Symptom Navi Program (SNP) is a nurse-led intervention supporting basic symptom self-management for patients with any cancer diagnosis. The SNP has been accepted by patients and healthcare professionals...
14.
Linnik J, Syedbasha M, Kaltenbach H, Vogt D, Hollenstein Y, Kaufmann L, et al.
J Infect Dis
. 2021 Aug;
225(8):1482-1493.
PMID: 34415049
Background: Influenza vaccination efficacy is reduced after hematopoietic stem cell transplantation (HSCT) and patient factors determining vaccination outcomes are still poorly understood. Methods: We investigated the antibody response to seasonal...
15.
Seydoux C, Medinger M, Gerull S, Halter J, Heim D, Chalandon Y, et al.
Ann Hematol
. 2020 Oct;
100(1):209-216.
PMID: 33098041
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior to subsequent...
16.
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, et al.
Blood Adv
. 2020 Aug;
4(15):3699-3707.
PMID: 32777066
Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there are excellent long-term data for intravenous...
17.
Burgener A, Bantug G, Meyer B, Higgins R, Ghosh A, Bignucolo O, et al.
Nat Immunol
. 2019 Sep;
20(10):1311-1321.
PMID: 31527833
Whether screening the metabolic activity of immune cells facilitates discovery of molecular pathology remains unknown. Here we prospectively screened the extracellular acidification rate as a measure of glycolysis and the...
18.
Drexler B, Passweg J, Tzankov A, Bigler M, Theocharides A, Cantoni N, et al.
Haematologica
. 2018 Nov;
104(4):710-716.
PMID: 30409796
The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of -V617F-positive myeloproliferative neoplasms. We...
19.
Driessen C, Muller R, Novak U, Cantoni N, Betticher D, Mach N, et al.
Blood
. 2018 Sep;
132(19):2097-2100.
PMID: 30237154
No abstract available.
20.
Hatalova A, Schwarz J, Gotic M, Penka M, Hrubisko M, Kusec R, et al.
Eur J Haematol
. 2018 Jul;
PMID: 30058088
Objectives: To present the Central European Myeloproliferative Neoplasm Organisation (CEMPO) treatment recommendations for polycythaemia vera (PV). Methods: During meetings held from 2015 through 2017, CEMPO discussed PV and its treatment...